XTRA:SY1Chemicals
Symrise (XTRA:SY1) Is Up 7.7% After Major Non-Cash Impairments Reshape Its 2025 Outlook
Symrise AG has disclosed that, in late 2025, it entered advanced talks to sell its terpenes business and recorded non-cash impairment charges of about €145.00 million on that unit and €150.00 million on its investment in Swedencare AB, materially affecting 2025 EBIT and EBITDA under IFRS 5.
These write-downs highlight a sharper refocus on higher-priority assets, while also signaling that prior expectations for 2025 results no longer align with current accounting realities.
We’ll now examine...